Celexion licensee BioAmber registers for IPO

Celexion LLC

Celexion licensee BioAmber registers for IPO

November 14, 2011

Today, BioAmber, a next generation chemicals company and licensee of Flagship portfolio company Celexion, announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of its common stock.

In March, Flagship portfolio company Celexion entered into an exclusive licensing agreement with BioAmber for technology related to the production of adipic acid and other chemical intermediates.  The current market for adipic acid is close to 3 million tons per year, worth approximately $8 billion at current market prices.